CLINICAL_TRIALS
trial_result
· 2012-09-03
Clinical Trial Update: Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care [Phase 3]
Summary
A Phase 3 study of eprotirome in patients with heterozygous familial hypercholesterolemia was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karo Bio AB | Conditions: Heterozygous Familial Hypercholesterolaemia | Phase 3 | Status: TERMINATED